MindWalk (NASDAQ:HYFT) Upgraded at Zacks Research

MindWalk (NASDAQ:HYFT) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Separately, Weiss Ratings started coverage on MindWalk in a research report on Wednesday, January 14th. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

MindWalk Stock Down 0.7%

NASDAQ HYFT opened at $1.38 on Monday. MindWalk has a 52-week low of $0.27 and a 52-week high of $3.25. The firm has a market cap of $63.70 million, a PE ratio of -2.30 and a beta of 0.51. The company has a quick ratio of 4.09, a current ratio of 4.19 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On MindWalk

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can boosted its holdings in MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after acquiring an additional 24,500 shares during the period. Jane Street Group LLC lifted its position in MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after purchasing an additional 96,018 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of MindWalk by 8.4% during the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares during the period. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.